While the tumor-associated antigens (SHARPIN, MRFAP1L1, PNMA2, AURKA, SERPINB1) were expressed at the transcript level in all ovarian cancer samples (n = 307/307, 100%), expression was less prevalent for the cancer-testis antigens (MAGEA4: n = 224/307, 73%; MAGEA12: n = 102/307, 33.2%; MAGEB4: n = 78/307, 25.4%; CTAG2: n = 76/307, 24.8%; XAGE3: n = 48/307, 15.6%, Figure 3). This evidence concerns the gene MAGEA12 and ovarian cancer.